Clinical trials: Known or Highly Suspected Body (Excluding CNS) Lesion
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with…
- Trial name
- LUMINA (NCT07472491)
- Testing
- Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
- Where
- 7 sites in United States, Georgia and 2 more
- Volunteers
- 640 people
- Sponsor
- GE Healthcare
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions
The purpose of this study is to evaluate the efficacy of HRS-9231 for Magnetic Resonance Imaging (MRI) of body regions excluding the Central Nervous System (CNS) in patients undergoing MRI examinations, using the patient's own…
- Trial name
- NCT07275723
- Testing
- HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI)
- Where
- 2 sites in China
- Volunteers
- 309 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd